Comparison of Walking in Water and on Land in People With Chronic Obstructive Pulmonary Disease (COPD)

August 19, 2021 updated by: Renae McNamara, European Respiratory Society

Determining the Metabolic Load of Walking in Water Compared to Walking on Land in People With COPD, Who Are Normal Weight and Obese, Compared to Peak Exercise Metabolic Response: a Prospective, Randomised Cross-over Pilot Trial

The purpose of this study is to evaluate the metabolic load during a single session of moderate intensity walking in water compared to walking on land (over-ground) in people with chronic obstructive pulmonary disease (COPD) who are normal weight and obese, compared with peak exercise metabolic response.

The hypothesis is that the metabolic load of walking at a moderate intensity in water will be greater than walking on land.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
      • Horn, Netherlands
        • Centre of intergrated rehabilitation for chronic organ failure

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • diagnosis of COPD (FEV1/FVC <0.7) in a clinically stable state (no acute exacerbation of COPD within the previous 4 weeks)
  • accepting of walking in water
  • BMI >/= 21 kg/m2

Exclusion Criteria:

  • long-term oxygen therapy
  • contraindications to entering a hydrotherapy pool

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: COPD (normal weight)
People with COPD (BMI 21 kg/m2 to 29 kg/m2)
Behavioral: Water-based walking

Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.

During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.

Behavioral: Land-based walking

Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.

During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.
Experimental: COPD (obese)
People with COPD (BMI >/= 30 kg/m2)
Behavioral: Water-based walking

Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.

During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.

Behavioral: Land-based walking

Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.

During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Breath-by-breath oxygen consumption (VO2)
Time Frame: Day of assessment during study measurement period (15 minutes)
Day of assessment during study measurement period (15 minutes)

Secondary Outcome Measures

Outcome Measure
Time Frame
Minute ventilation (VE)
Time Frame: Day of assessment during study measurement period (15 minutes)
Day of assessment during study measurement period (15 minutes)

Other Outcome Measures

Outcome Measure
Time Frame
Dyspnoea, measured by the modified Borg 0-10 category ratio scale
Time Frame: Day of assessment during study measurement period (15 minutes)
Day of assessment during study measurement period (15 minutes)
Exertion, measured by the modified Borg 0-10 category ratio scale
Time Frame: Day of assessment during study measurement period (15 minutes)
Day of assessment during study measurement period (15 minutes)
Oxygen saturation
Time Frame: Day of assessment during study measurement period (15 minutes)
Day of assessment during study measurement period (15 minutes)
Heart rate
Time Frame: Day of assessment during study measurement period (15 minutes)
Day of assessment during study measurement period (15 minutes)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

European Respiratory Society

Collaborators

Center for Integrated Rehabilitation and Organ Failure Horn

Investigators

  • Study Director: Martijn A Spruit, PhD, Centre of integrated rehabilitation for chronic organ failure

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2016

Primary Completion (Actual)

January 1, 2020

Study Completion (Actual)

January 1, 2020

Study Registration Dates

First Submitted

April 7, 2016

First Submitted That Met QC Criteria

April 27, 2016

First Posted (Estimate)

April 29, 2016

Study Record Updates

Last Update Posted (Actual)

August 25, 2021

Last Update Submitted That Met QC Criteria

August 19, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ERS STRTF 2015 - 9368

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe